
Boston Scientific’s TAVR Device Faces Setback in Major Clinical Trial
Quick Summary Trial Outcome: Boston Scientific’s Acurate neo2 transcatheter aortic valve replacement (TAVR) system missed its primary endpoint in a critical trial. Comparison Results: Acurate